Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Published Online: 2025-03-?
Journal: Journal of Clinical OncologyLoading...
Authors: Adam J. Olszewski•Ann S. LaCasce•Austin I. Kim•Benjamin L. Lampson•Caron A. Jacobson•Christine E. Ryan•Claire Greenman•David C. Fisher•Heather A. Walker•Inhye E. Ahn•Jennifer L. Crombie•Jennifer R. Brown•Jon E. Arnason•Josie Montegaard•Matthew S. Davids•Matthew Weinstock•Philippe Armand•Stacey M. Fernandes•Steve Lo•Svitlana Tyekucheva•Victoria Patterson•Yue Ren
